Skip to content

Neutrophil CD64 for Early Diagnosis of Nosocomial Infection in Preterm Newborns

Rapid Quantitative Neutrophil CD64 Measurement for Early Diagnosis of Nosocomial Infection in Preterm Newborns

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01951781
Acronym
NEOCD64
Enrollment
153
Registered
2013-09-27
Start date
2013-06-30
Completion date
2015-11-30
Last updated
2015-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nosocomial Infection

Keywords

marker CD64, blood sample, nosocomial infection, preterm newborn

Brief summary

Diagnosis of late-onset sepsis is difficult in the absence of specific clinical signs and biological markers in the infection initial phase .The aim of this study is to determine the performance of a new infection marker : Neutrophil CD64 for early diagnosis in nosocomial infection (NI) in preterm newborns. METHODS : * Monocentric prospective study including preterm newborn infants (\<37 weeks of gestationnal age ) with clinical suspicion of nosocomial infection in a neonatal intensice care unit (Neonatal intensive care unit of Montpellier, France). * Patients will be enrolled in the study after informed consents. Rapid and automated CD64 measurment will be realized during the conventional blood sample including C-Reactive Protein (CRP), Procalcitonin (PCT) and blood culture. * Broad-spectrum antibiotic therapy can be started on the advice of clinician and blinded the result of CD64. Patients will be then classed in three groups using CDC criteria (center for disease control) : 1-no infection, 2-infection, 3-possible infection during the multidisciplinary staff. Specificity, sensitivity, negative and positive value of CD64 will be calculated and the performances of CRP, PCT and CD64 will be compared. 153 patients are needed in the study enrolled during a period of 12 months. PERSPECTIVES Neutrophil CD64 monitoring might be help clinicians to manage nosocomial infections in neonates.CD64 allow to integrate in a decision algorithm with the determination of the best cut-off value to faster processing nosocomial infections and could help to reduce unnecessary antibioc therapy. A rapid technique for determination of CD64 should be readily available in our unit.

Interventions

OTHERblood sample

blood sample in newborn preterms suspected of nosocomial infection (neoCD64 arm) When late-onset sepsis is suspected, blood samples are obtained from peripheral veins for a complete blood count, measurement of CRP and PCT concentration and one bacterial culture acording to the current recommendation of the CDC. CD64 concentration measurement require 0.2 ml aditionnal blood.

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Caregiver)

Eligibility

Sex/Gender
ALL
Age
No minimum to 5 Months
Healthy volunteers
No

Inclusion criteria

* preterm newborn (\<37 weeks of gestationnal age ) * undergoing symptoms of late-onset-sepsis * written informed consent obtained from the parents

Exclusion criteria

* patient undergoing antibiotic therapy * patient undergoing surgery in the last seven days, * patient with severe congenital malformation * necrotizing enterocolitis * parents unable to understand the purpose of the study * no affiliation to social security

Design outcomes

Primary

MeasureTime frame
proportion of negatives (healthy patient) which are correctly identified as suchday 1

Secondary

MeasureTime frameDescription
positive predictiveCD64 valueday 1
proportion of positives (sikness)which are correctly defined as suchday 1sensibility of CD64 value
negative predictive CD64 valueday 1

Countries

France

Contacts

Primary ContactGilles CAMBONIE, Professor
g-cambonie@chu-montpellier.fr33467336609
Backup ContactSabine DURAND, doctor
s-durand@chu-montpellier.fr33467336609

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026